Diabetes Care 36, 19331940.CrossRefGoogle ScholarPubMed Scott, RA, Freitag, DF, Li, L, Chu, AY, Surendran, P, Young, R, Grarup, N, Stanckov, A, Chen, Y, Varga, TV and Yaghootkar, H (2016) A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease
[PMC free article: PMC3425013] [PubMed: 22923682] 3
The gene NCU03826 that was speculated to encode K-NMT in a patent application (Kang et al., 2013) did not result in a biosensor response that would indicate improved L-carnitine levels and the supplementation of lysine and methionine as precursors did not change this outcome (data not shown)
The molecular synergy between these peptides occurs at multiple levels
CJC-1295 and ipamorelin are not FDA-approved for any indication
It should be avoided however if you are reactive to any of the ingredients